Valeant Pharmaceuticals: Bigger is Better

Though the sale of its iNova unit brings Valeant Pharmaceuticals close to meeting its goal of $5 billion in debt reduction by February 2018, the drug maker may need to step up its deal making if it wants to take a real bite out of its debt load.